Impact of low dose naltrexone (LDN) on antiretroviral therapy (ART) treated HIV+ adults in Mali: A single blind randomized clinical trial

@article{Traore2011ImpactOL,
  title={Impact of low dose naltrexone (LDN) on antiretroviral therapy (ART) treated HIV+ adults in Mali: A single blind randomized clinical trial},
  author={A. K. Traore and Oumar Thiero and Sounkalo Dao and Fadia F. C. Kounde and Ousmane Faye and Mamadou Ciss{\'e} and Jaquelyn B. McCandless and Jack M. Zimmerman and Karim Coulibaly and Ayouba Diarra and Mamadou S. Keita and Souleymane Diallo and Ibrahima G. Traore and Ousmane A. Koita},
  journal={Journal of AIDS and HIV Research},
  year={2011},
  volume={3},
  pages={189-198}
}
To implement an immuno-regulatory approach for reducing or preventing the onset of AIDS symptoms in HIV+ individuals we conducted a single blind nine-month randomized clinical trial to evaluate the impact of low-dose naltrexone (LDN) on asymptomatic HIV+ Mali adults undergoing antiretro virial (ART) treatment with CD4 counts below 350 cell/mm3. We measured differences between groups in CD4 count, CD4%, hemoglobin, viral load, interferon alpha, and standard chemistry panel five times during the… 
View via Publisher
ldnafricaaids.org
7 Citations

Figures and Tables from this paper

7 Citations

Low-dose naltrexone as a treatment for chronic fatigue syndrome

This series of three case reports compiled by people with long-term ill-health due to chronic fatigue syndrome shows the range of responses they observed when taking LDN, from life changing to a reduction in some symptoms only.

Evaluation of therapeutic effect of low dose naltrexone in experimentally-induced Crohn's disease in rats

Approaches to the Development of a Low-dose Naltrexone Preparation in the Form of a Nasal Spray (Review)

Current research in the field of low-dose naltrexone application, its mechanisms of action, and possible areas of application in medical practice are presented and an alternative route of administration such as intranasal is considered.

Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion

A case of a 50-year-old male with a prolonged survival and a past medical history of prostate and lung cancer is presented and a unique mechanism allowing LDN to affect tumors including non-small cell lung cancer at the cellular level by augmenting the immune system is proposed.

Alcohol use disorders negatively influence antiretroviral medication adherence among men who have sex with men in Peru

Evidence-based strategies targeting AUDs are likely to directly improve ART adherence and indirectly improve overall individual health, HIV treatment engagement, and reduce transmission to sexual partners among this vulnerable and disproportionally affected population.

Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis

Findings confirm the safety of oral naltrexone when used in licensed indications and encourage investments to undertake efficacy studies in unlicensed indications and confirm the risk of serious adverse events over placebo.

Ex vivo studies for the passive transdermal delivery of low-dose naltrexone from a cream; detection of naltrexone and its active metabolite, 6β-naltrexol, using a novel LC Q-ToF MS assay

The cream formulated into a cream for the delivery of naltrexone may be an effective formulation for the sustained transdermal delivery of LDN and an analytical technique for the quantification of NTX and its active metabolite 6-β-naltrexol (NTXol) duringtransdermal diffusion cell permeation studies.

References

SHOWING 1-10 OF 21 REFERENCES

CD4+ T-Lymphocytes Natural Decrease in HAART-Naïve HIV-Infected Adults in Abidjan

Estimates of the CD4 natural decrease in sub-Saharan African patients, while they did not experience any episode of severe morbidity and before they initiate HAART, are in the bracket of those previously reported in industrialized countries.

Naltrexone potentiates anti-HIV-1 activity of antiretroviral drugs in CD4+ lymphocyte cultures.

Darunavir: pharmacokinetics and drug interactions.

Reports from resource-limited countries suggest that initial ART programmes are as effective as in resource-rich countries, which should limit HIV drug resistance if programme effectiveness continues during scale-up.

Low-Dose Naltrexone Therapy Improves Active Crohn's Disease

Low-dose naltrexone (LDN) therapy appears effective and safe in subjects with active Crohn's disease and further studies are needed to explore the use of this compound.

The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.

We evaluated three cellular and five serologic markers that are affected by infection with the human immunodeficiency virus type 1 (HIV-1) for their ability to predict the progression to clinical…

Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy

Evidence from randomised controlled trials supports the use of triple therapy but there is inadequate evidence for quadruple or higher combinations.

The World Health Organization's global strategy for prevention and assessment of HIV drug resistance

Reports from resource-limited countries suggest that initial ART programmes are as effective as in resource-rich countries, which should limit HIV drug resistance if programme effectiveness continues during scale-up.

Mu-opioid modulation of HIV-1 coreceptor expression and HIV-1 replication.

The capacity of mu-opioids to increase HIV-1 coreceptor expression and replication may promote viral binding, trafficking of HIV- 1-infected cells, and enhanced disease progression.

μ-opioid modulation of HIV-1 coreceptor expressionand HIV-1 replication

Predicting AIDS-related events using CD4 percentage or CD4 absolute counts

The CD4 percentage was an unsurpassed predictor of the occurrence of AIDS-related events when all subsets of patients are considered and the extra time and expense of measuring the CD4 absolute count may be unnecessary.